Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally

benzinga.com/analyst-stock-ratings/initiation/25/12/49142994/analysts-see-big-upside-for-newly-listed-molecular-diagnostic-firm-billiontoone

BillionToOne, Inc., (NASDAQ:BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million.
The company, a commercial-stage molecular diagnostics company, offers specialized tests in prenatal genetics and…

This story appeared on benzinga.com, 2025-12-01 17:53:47.
The Entire Business World on a Single Page. Free to Use →